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Mary E. D. Flowers,1,2 Barry Storer,1,3 Paul Carpenter,1,4 Andrew R. Rezvani,1,2
Afonso C. Vigorito,5 Paulo V. Campregher,1 Carina Moravec,1 Hans-Peter Kiem,1,2
Matthew Fero,1,2 George Georges,1,2 Edus Warren,1,2 Stephanie Lee,1,2 Jean E. Sanders,1,4
Fred Appelbaum,1,2 Paul J. Martin1,2We analyzed outcomes for 668 patients who had systemic treatment for chronic graft-versus-host disease
(cGVHD) to assess the utility of early treatment change for exacerbation of cGVHD as a surrogate for sur-
vival endpoints in clinical trials. Fifty-six percent of patients had treatment change within 2 years after diag-
nosis of cGVHD. The median onset of treatment change was 4.4 months (range: 0.3-50 months). The
cumulative incidence of nonrelapse mortality (NRM) at 2 years was 16%, and overall survival (OS) at 2 years
was 74%. In time-dependent Cox models, treatment change was associated with an increase in risk of NRM
(hazard ratio, 2.53; 95% confidence interval, 1.7-3.7; P\.0001). The hazard ratio was attenuated by 6% per
month of delay in treatment change. Our results confirm that exacerbation of cGVHD is associated with an
increased risk of NRM and with decreased OS, but the strength of this association is not large enough to
allow the use of early exacerbation as a surrogate for survival endpoints in clinical trials. Other measures
of clinical benefit, such as response, will need to be developed as endpoints in phase II trials for patients
with cGVHD.
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Chronic graft-versus-host disease (cGVHD) is the
major determinant of both late nonrelapse morbidity
and mortality (NRM) after allogeneic hematopoietic
cell transplantation (HCT) [1-3]. In addition to in-
creased risk of NRM, patients with cGVHD have de-
creased performance, impaired quality of life, and
delayed immune reconstitution [4-6]. In most cases,
resolution of cGVHD requires prolonged systemic
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6/j.bbmt.2008.09.017Clinical trials of treatment for cGVHD have been
hampered by the lack of easily documented early indi-
cators of clinical benefit. Demonstration of prolonged
survival or a shorter time to resolution of cGVHDmay
be feasible for pivotal phase III studies, but ascertain-
ment of these endpoints occurs too late to be useful
for phase II studies [8,9]. A National Institute of
Health (NIH) consensus development project recom-
mended an approach that could be used to measure re-
sponse in clinical trials for treatment of cGVHD, but
these recommendations have not yet been validated
[10]. Implementation of these recommendations has
been difficult, because they require a much larger bur-
den of documentation than would ordinarily be re-
quired for clinical practice. In addition, certain
features of cGVHDhave important qualitative charac-
teristics such as sclerosis and intensity of erythema that
are not readily amenable to quantitative measurement.
Identification of more accessible validated end-
points indicating clinical benefit could facilitate the
conduct of clinical trials in cGVHD. Kim et al. [11] re-
cently proposed that an early flare or exacerbation of
cGVHD could be used as an endpoint in clinical trials.
Early flare was strongly associated with decreased
Table 1. Characteristics of the Study Cohort (n 5 668)
Characteristic N (%)
Demographic and graft characteristics
Patient age $50 years 271 (41)
Unrelated donor 354 (53)
HLA-mismatched recipient 105 (16)
Female donor, male recipient 187 (28)
Mobilized blood cell graft 573 (86)
Cord blood 11 (2)
Nonmyeloablative conditioning regimens 222 (33)
Myeloablative conditioning regimens:
– with total body irradiation 186 (28)
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GVHD-specific survival at 2 years was 96% among
27 patients who had no flare, 65% among 34 patients
with a first flare more than 78 days after diagnosis of
cGVHD, and 33% among 35 patients who had a first
flare within 78 days after diagnosis [11]. Prompted
by this report, we reviewed outcomes among patients
with cGVHD at our center in an effort to validate
these results and to assess the utility of early flare as
a surrogate for survival in clinical trials.– without total body irradiation 260 (39)
Chronic GVHD characteristics at onset
Diagnosis during steroid treatment 244 (37)
Progressive 77 (12)
Quiescent 438 (66)
De novo 153 (23)
Platelet count <100,000/mL 201 (30)PATIENTAND METHODS
We reviewed data collected in real time for 668
consecutive patients who were given initial systemic
treatment for cGVHD diagnosed after May 1, 2001,
following a first allogeneic HCT after myeloablative
or nonmyeloablative conditioning regimens. Patients
who had recurrent malignancy before the diagnosis
of cGVHD were excluded. NIH criteria were used
for the diagnosis of classic cGVHD, except that an oc-
ular clinical score of 2 or 3 without Schirmer’s test was
accepted as sufficient to define ocular involvement
[12]. The cohort did not include patients with persis-
tent, recurrent, or delayed-onset acute GVHD
(aGVHD) [12]. We used the first treatment change
as a surrogate for exacerbation of cGVHD, and we
evaluated the association of treatment change with
NRM and overall survival (OS).
Change of Treatment
Dates and the reasons for change of treatment after
the initial systemic treatment for cGVHD have been
prospectively recorded at our center since May 2001.
Change of treatment was defined as (1) addition of
a new systemic medication to control cGVHD, (2) in-
crease in the dose of prednisone to at least 1 mg/kg ev-
ery other day for control of cGVHD, or (3) addition of
a topical treatment for cGVHD involving a previously
unaffected site. Change of treatment because of toxic-
ity alone was not included, because the focus of the
study was to use change of treatment as a surrogate
for ‘‘flare’’ or inadequate control of cGVHD.
Statistical Methods
Results were analyzed according to information
available as of May 2008. Cox proportional hazards
regression was used to identify risk factors for treat-
ment change, and time-dependent Cox proportional
hazards regression was used to evaluate the association
of treatment change with mortality. Cumulative
incidence estimates and confidence intervals (CIs)
were evaluated as previously described [13]. Factors
evaluated for association with treatment change
included age of the patient at time of transplant, recip-
ient HLA-mismatching (ie, any graft-versus-host[GVH] mismatching at HLA-A, -B, -C, -DRB1, or
-DQB1), donor type (ie, unrelated and related), recip-
ient and donor sex, type of graft (ie, marrow or mobi-
lized blood), type of preparative regimen (ie,
nonmyelobative, myeloablative with and without total
body irradiation), onset of cGVHD during systemic
glucocorticoid treatment, type of onset of cGVHD
(ie, progressive, de novo, quiescent), platelet count
\100,000/mL at onset of cGVHD, and sites involved
at the onset of cGVHD [7,14].RESULTS
The median patient age at transplant of the cohort
was 46.7 years (range: 0.5-73 years). Four hundred
forty-six patients (67%) received a myeloablative con-
ditioning regimen pretransplant. Other demographic
and graft characteristics for the 668 patients are sum-
marized in Table 1 and Figure 1. cGVHD was diag-
nosed during steroid treatment in 37% of the
patients, and 30% had a platelet count\100,000/mL
at the onset of cGVHD. Overall, 49% of patients had
at least 1 of these risk factors as an indicator or poor
prognosis. The distribution of organ involvement was
typical for patients with cGVHD. Among the 668 pa-
tients, 56% had a treatment change within 2 years after
beginning systemic treatment for cGVHD, and the
median interval time from initial systemic treatment
to the first treatment change was 4.4 months (range:
0.3-54 months) (Figure 2A). Treatment change was
associated with 2 risk factors: skin involvement at the
onset of cGVHD and use of a female donor for male
recipients (Table 2). The cumulative incidence of
NRM at 2 years was 16% (95% CI, 13%-19%)
(Figure 2B), and OS at 2 years was 74% (95% CI,
70%-77%). As shown in Figure 3, the cumulative inci-
dence of NRMwas higher for patients who had a treat-
ment change within 4 months after the initiation of
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Figure 1. Sites affected by cGVHD at time of diagnosis. Columns show
the proportions of patients with organs affected by cGVHD at diagnosis.
Table 2. Risk Factors for Treatment Change
Univariate Multivariate
Characteristic HR (95% CI) P HR (95% CI) P
Female donor,
male recipient
1.31 (1.1-1.6) .02 1.31 (1.0-1.6) .01
Skin involved
at onset
1.26 (1.0-1.6) .04 1.26 (1.0-1.6) .04
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not (27% versus 12%, respectively).
As expected, time-dependent analysis showed that
treatment change after initial systemic treatment for
cGVHD was associated with an increased risk of
NRM (Table 3). Because the median time of treatment
change was 4.3 months after initial systemic treatment
for cGVHD, we evaluated results for patients who had
a treatment change before 4 months compared toFigure 2. (A) Cumulative incidence of first change in treatment after
initial systemic treatment for cGVHD. (B) Cumulative incidence of
NRM after the initial diagnosis of cGVHD.change after 4 months. As shown in Table 3, the asso-
ciation with NRM was stronger for early treatment
change than for late change, although the difference
between early and late change was not statistically sig-
nificant (P 5 .06). A similar trend was found when we
evaluated results for treatment change before 6months
compared to treatment change after 6 months (P 5
.09). When time of change was analyzed continuously,
change at 4 months was associated with a 2.5-fold in-
crease in NRM, and for each month of delay in treat-
ment change, this effect on NRM was attenuated by
a factor of 0.94, equivalent to a 6% reduction per
month (Table 3). An association between treatment
change and overall mortality was also noted, but the
hazard ratios were lower (data not shown). For each
month of delay in treatment change, the effect on over-
all mortality was attenuated by a factor of 0.93.DISCUSSION
Most phases II studies have relied on ‘‘response’’ as
the primary endpoint in clinical trials for cGVHD. Al-
though ‘‘response’’ is easily recognized in clinical prac-
tice, documentation of response for purposes of
clinical trials (ie, convincing other people who cannot
interview or examine the patient) is much more diffi-
cult and burdensome. Disease characteristics such as
the severity of sclerosis or fasciitis and the intensityFigure 3. The cumulative incidence of NRM was higher for patients
who had a treatment change within 4 months after initial systemic treat-
ment for cGVHD (solid line) than for thosewho did not have a treatment
change during the first 4 months (dashed line).
Table 3. Factors Associated with Nonrelapse Mortality
Characteristic HR (95% CI) P
Treatment change at any time versus none 2.53 (1.7-3.7) <.0001
Treatment change before 4 months versus none 2.84 (1.9-4.2)
Treatment change after 4 months versus none 1.84 (1.1-3.1)
Effect after versus before 4 months .06
Treatment change before 6 months versus none 2.72 (1.8-4.0)
Treatment change after 6 monthes versus none 1.77 (1.0-3.2)
Effect after versus before 6 months .09
Treatment change at 4 months versus none 2.45 (1.7-3.6) <.0001
Relative effect per month 0.94 (0.89-0.99) .02
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selves to quantitative measurement, which makes it
difficult to document the magnitude of change from
baseline. The difficulty of documenting response
made it attractive to consider change of treatment as
an alternative endpoint for clinical trials, because this
endpoint is objective and easy to document, although
it measures failure rather than success and would be
susceptible to bias in open-labeled studies.
Our results confirmed those reported by Kim et al.
[11] in demonstrating that exacerbation of cGVHD is
associated with an increased risk of NRM and with
decreased OS. As in the Korean study, the associations
with NRM and survival endpoints are stronger for
early exacerbation than for late exacerbation. Skin in-
volvement at onset of cGVHD and the use of female
donor for male recipients were the only risk factors as-
sociated with treatment change. Because accrual of the
cohort antedated the NIH consensus definition of se-
verity scores for cGVHD [12], these factors could
not be analyzed as risk factors for change of therapy
and nonrelapse survival in our study.
We evaluated whether early treatment change
could be used as a surrogate for NRM in clinical trials
(see Supplemental Table). In our cohort, 27% of the
patients had a treatment change within 4 months after
diagnosis of cGVHD, and the risk of NRM at 2 years
for these patients was 27%. The contribution to NRM
at 2 years among these patients is 0.27  0.27, or 7%.
Among the remaining 73% of patients who did not
have a treatment change during the first 4 months,
the risk of NRM was 12%, and the contribution to
NRM at 2 years among these patients is 9%. The total
NRM for both groups at 2 years is 16%. If we had
a therapy that could eliminate the need for any treat-
ment change during the first 4 months after diagnosis,
the expected NRM at 2 years would be 12%, only 4
percentage points lower than historical results. Under
the same assumptions, the difference in overall mortal-
ity would be only 2 percentage points. When the same
analysis was repeated using 1 year (by which time 47%
of patients had a treatment change) instead of 4
months as the time point for assessment of treatment
change, the difference in NRM at 2 years was only 3
percentage points.Our results indicate that differences in the strength
of associations between early change of treatment and
NRM or survival are not large enough to allow the use
of early exacerbation as a surrogate endpoint for NRM
or survival in clinical trials for treatment of cGVHD.
In evaluating our results, it should be noted that the
acuity of cGVHD was higher in the Korean cohort
[11] than in our cohort, as indicated by a higher inci-
dence of progressive onset (38% versus 12%) and
thrombocytopenia (49% versus 30%), a higher inci-
dence of exacerbation at 2 years (70% versus 56%),
a shorter time to exacerbation, (2.4 versus 4.4 months),
and a higher incidence of NRM at 2 years (39% versus
16%), respectively. In addition, the previous report in-
cluded patients with late, persistent, or recurrent
aGVHD, whereas our cohort included only patients
with classic cGVHD and overlap syndrome [12].
These differences might account for the stronger asso-
ciation between early change of treatment and NRM
in the Korean study than in our study. We conclude
that other measures of clinical benefit, such as re-
sponse, will need to be developed as endpoints in phase
II trials of treatment for cGVHD.ACKNOWLEDGEMENTS
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